CN115368423B - 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途 - Google Patents

还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途 Download PDF

Info

Publication number
CN115368423B
CN115368423B CN202210168280.1A CN202210168280A CN115368423B CN 115368423 B CN115368423 B CN 115368423B CN 202210168280 A CN202210168280 A CN 202210168280A CN 115368423 B CN115368423 B CN 115368423B
Authority
CN
China
Prior art keywords
disodium salt
crystal
reduced
nicotinamide mononucleotide
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210168280.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN115368423A (zh
Inventor
高省
余建军
徐钦源
李银山
刘佳玲
常留磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yinfu Pharmaceutical Technology Shanghai Co ltd
Original Assignee
Yinfu Pharmaceutical Technology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yinfu Pharmaceutical Technology Shanghai Co ltd filed Critical Yinfu Pharmaceutical Technology Shanghai Co ltd
Priority to CN202210168280.1A priority Critical patent/CN115368423B/zh
Publication of CN115368423A publication Critical patent/CN115368423A/zh
Priority to US18/840,839 priority patent/US12570683B2/en
Priority to KR1020247028723A priority patent/KR20240167631A/ko
Priority to EP23759030.2A priority patent/EP4484438A1/en
Priority to PCT/CN2023/075226 priority patent/WO2023160405A1/zh
Priority to CA3244879A priority patent/CA3244879A1/en
Priority to CN202380016799.0A priority patent/CN118525027A/zh
Priority to JP2024550658A priority patent/JP7762933B2/ja
Priority to AU2023223327A priority patent/AU2023223327B2/en
Priority to NZ813980A priority patent/NZ813980A/en
Application granted granted Critical
Publication of CN115368423B publication Critical patent/CN115368423B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/002—Preparations for repairing the hair, e.g. hair cure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
CN202210168280.1A 2022-02-23 2022-02-23 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途 Active CN115368423B (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN202210168280.1A CN115368423B (zh) 2022-02-23 2022-02-23 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
KR1020247028723A KR20240167631A (ko) 2022-02-23 2023-02-09 환원형 β-니코틴아미드 모노뉴클레오티드 이나트륨염의 다결정형 및 이의 제조 방법과 용도
US18/840,839 US12570683B2 (en) 2022-02-23 2023-02-09 Polymorphic form of reduced beta-nicotinamide mononucleotide disodium salt, and preparation method therefor and use thereof
EP23759030.2A EP4484438A1 (en) 2022-02-23 2023-02-09 POLYMORPHIC FORM OF REDUCED ß-NICOTINAMIDE MONONUCLEOTIDE DISODIUM SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOF
PCT/CN2023/075226 WO2023160405A1 (zh) 2022-02-23 2023-02-09 还原型β‐烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
CA3244879A CA3244879A1 (en) 2022-02-23 2023-02-09 POLYMORPHIC FORM OF DISODIUM SALT OF REDUCED BETA-NICOTINAMIDE MONONUCLEOTIDE, ITS PREPARATION PROCESS AND ITS USE
CN202380016799.0A CN118525027A (zh) 2022-02-23 2023-02-09 还原型β‐烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
JP2024550658A JP7762933B2 (ja) 2022-02-23 2023-02-09 還元型β－ニコチンアミドモノヌクレオチド二ナトリウム塩の結晶多形およびその製造方法と使用
AU2023223327A AU2023223327B2 (en) 2022-02-23 2023-02-09 POLYMORPHIC FORM OF REDUCED β-NICOTINAMIDE MONONUCLEOTIDE DISODIUM SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOF
NZ813980A NZ813980A (en) 2022-02-23 2023-02-09 Polymorphic form of reduced β-nicotinamide mononucleotide disodium salt, and preparation method therefor and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210168280.1A CN115368423B (zh) 2022-02-23 2022-02-23 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途

Publications (2)

Publication Number Publication Date
CN115368423A CN115368423A (zh) 2022-11-22
CN115368423B true CN115368423B (zh) 2025-05-09

Family

ID=84060296

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210168280.1A Active CN115368423B (zh) 2022-02-23 2022-02-23 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
CN202380016799.0A Pending CN118525027A (zh) 2022-02-23 2023-02-09 还原型β‐烟酰胺单核苷酸二钠盐的多晶型及其制法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202380016799.0A Pending CN118525027A (zh) 2022-02-23 2023-02-09 还原型β‐烟酰胺单核苷酸二钠盐的多晶型及其制法和用途

Country Status (9)

Country Link
US (1) US12570683B2 (https=)
EP (1) EP4484438A1 (https=)
JP (1) JP7762933B2 (https=)
KR (1) KR20240167631A (https=)
CN (2) CN115368423B (https=)
AU (1) AU2023223327B2 (https=)
CA (1) CA3244879A1 (https=)
NZ (1) NZ813980A (https=)
WO (1) WO2023160405A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115368423B (zh) 2022-02-23 2025-05-09 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
WO2023179793A1 (zh) * 2022-03-25 2023-09-28 成都嘉葆药银医药科技有限公司 一种1H-吡咯并[2,3-c]吡啶类化合物的晶型及其制备方法
CN119320416B (zh) * 2023-11-10 2026-01-06 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸钙盐的多晶型及其制法和用途
CN119978042B (zh) * 2023-11-10 2025-09-09 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸钙盐的无定型及其制法和用途
WO2025142856A1 (ja) * 2023-12-25 2025-07-03 株式会社カネカ 還元型β－ニコチンアミドモノヌクレオチドのカルシウム塩及びその製造方法
WO2025142857A1 (ja) * 2023-12-25 2025-07-03 株式会社カネカ 還元型β－ニコチンアミドモノヌクレオチドの塩及びその製造方法
CN120424148B (zh) * 2024-02-02 2025-10-17 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸盐及其组合物、制法和用途
CN118546191A (zh) * 2024-07-29 2024-08-27 邦泰生物工程(深圳)有限公司 还原型β-烟酰胺单核苷酸一钠盐晶型及其制备方法和应用
WO2026075119A1 (ja) * 2024-10-04 2026-04-09 株式会社カネカ 還元型ニコチンアミドモノヌクレオチドの製造方法
CN119143826B (zh) * 2024-11-19 2025-03-28 邦泰生物工程(深圳)有限公司 还原型β-烟酰胺单核苷酸二钠盐无定型化合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490676A (zh) * 2019-11-19 2021-10-08 清华大学 Nmn衍生物的合成方法和nmn及其衍生物的医学应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6352825B2 (ja) 2015-01-23 2018-07-04 株式会社ベスビオ 化粧料
EP3274357B1 (en) * 2015-03-27 2019-12-11 Cornell University Efficient synthesis of nicotinamide mononucleotide
KR20250080927A (ko) 2018-05-15 2025-06-05 점프스타트 퍼틸리티 피티와이 엘티디 노화방지제로서의 니코틴산 모노뉴클레오타이드의 무기 염
AU2019314476A1 (en) 2018-08-01 2021-02-25 Roland Dolle Quaternary ammonium salts of nicotinic acid and nicotinamide mononucloetides and ribosides as anti-aging agents
CN109350622A (zh) 2018-10-17 2019-02-19 深圳市龙格生技术有限公司 烟酰胺核糖及其衍生物与吡咯喹啉醌及其钠盐的组合工艺
CN110845548B (zh) * 2019-11-22 2021-02-09 武汉一若生物材料有限公司 一种制备β-烟酰胺单核苷酸及其钠盐的方法
CN112538101B (zh) * 2020-08-13 2026-02-03 常州博海威医药科技股份有限公司 一种β烟酰胺单核苷酸的新晶型及其制备方法和用途
CN114075582A (zh) 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种d-核糖-5-磷酸的制备方法和应用
CN113332304A (zh) 2021-06-08 2021-09-03 深圳市旷逸生物科技有限公司 烟酰胺单核苷酸在制备心肌缺血再灌注损伤药物中的应用
CN113292619B (zh) * 2021-06-18 2022-04-22 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸-异烟碱共晶体及其组合物
CN115368423B (zh) * 2022-02-23 2025-05-09 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490676A (zh) * 2019-11-19 2021-10-08 清华大学 Nmn衍生物的合成方法和nmn及其衍生物的医学应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RN:108347-85-9;Chemical Abstracts Service;《Database Registry[Online]》;19870530;全文 *
Yan Liu,等.Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth.《J. Proteome Res.》.2021,第20卷第2596−2606页. *
Yao Li u,等.Engineering the biomimetic cofactors of NMNH for cytochrome P450 BM3 based on binding conformation refinement.《RSC Adv.》.2021,第11卷第12036–12042页. *

Also Published As

Publication number Publication date
CN118525027A (zh) 2024-08-20
US20250163092A1 (en) 2025-05-22
EP4484438A1 (en) 2025-01-01
JP7762933B2 (ja) 2025-10-31
CN115368423A (zh) 2022-11-22
CA3244879A1 (en) 2025-06-13
NZ813980A (en) 2026-01-30
AU2023223327B2 (en) 2025-10-09
US12570683B2 (en) 2026-03-10
KR20240167631A (ko) 2024-11-27
AU2023223327A1 (en) 2024-09-12
JP2025508874A (ja) 2025-04-10
WO2023160405A1 (zh) 2023-08-31

Similar Documents

Publication Publication Date Title
CN115368423B (zh) 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
CZ281318B6 (cs) Monohydrát mometasonfuroátu, způsob přípravy této látky a přípravy lékových kompozic z ní
CN103833626A (zh) 西达本胺的晶型及其制备方法与应用
CN103360391A (zh) 阿哌沙班新晶型及其制备方法
WO2022033589A1 (zh) 一种β烟酰胺单核苷酸的新晶型及其制备方法和用途
CN119019375A (zh) 一种瑞司美替罗新晶型及其制备方法
CN112209887B (zh) 一种5-氟尿嘧啶与山奈酚的共晶及其制备方法
KR20180036722A (ko) 빌라스틴의 결정형 및 그의 제조 방법
US20250388616A1 (en) POLYMORPHIC FORM OF REDUCED ß-NICOTINAMIDE MONONUCLEOTIDE CALCIUM SALT, AND PREPARATION METHOD AND USE THEREFOR
US20260015377A1 (en) Crystalline form i of reduced nicotinamide mononucleotide disodium monohydrate and preparation method therefor
WO2008092327A1 (fr) Cristaux demi-hydratés de voglibose, leur procédé de préparation, et préparation pharmaceutique les contenant
CN119978042B (zh) 还原型β-烟酰胺单核苷酸钙盐的无定型及其制法和用途
CN113045554A (zh) 一种非索替尼晶型及其制备方法
CN114349809A (zh) β-烟酰胺单核苷酸的晶型A及其制备方法
CN111995571A (zh) 一种瑞戈非尼与马来酸的共晶及其制备方法
CN110964017A (zh) 瑞博西尼单琥珀酸盐的多晶型物及其制备方法和用途
KR20250012075A (ko) 트리아진디온계 유도체의 결정형 및 제조 방법
HK40121709A (zh) 还原型β-烟醯胺单核苷酸钙盐的无定型及其制法和用途
CN119841853A (zh) 一种嘧啶甲酰胺类化合物的晶型及其制备方法
HK40091831A (zh) 一种三亚乙基四胺四氢氯化物及其制备方法与组合物
CN114957382A (zh) 氘代尼马瑞韦晶型i及其制备方法
WO2022194160A1 (zh) 非索替尼固体形式及其制备方法
KR20230087557A (ko) 로레시비빈트의 고상형

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant